查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血紅蛋白疾病全球市場規模、份額和行業趨勢分析報告：2022-2028 年按類型、分銷渠道、治療方法和地區分類的展望和預測
市場調查報告書
商品編碼
1172711

血紅蛋白疾病全球市場規模、份額和行業趨勢分析報告：2022-2028 年按類型、分銷渠道、治療方法和地區分類的展望和預測

Global Hemoglobinopathies Market Size, Share & Industry Trends Analysis Report By Type, By Distribution Channel, By Therapy, By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 209 Pages | 訂單完成後即時交付

價格

血紅蛋白疾病的全球市場規模預計到 2028 年將達到 60 億美元，預測期內復合年增長率為 5.6%。

例如，一種由不穩定的血紅蛋白導致紅細胞變形或受損而引起的血液疾病稱為鐮狀細胞病 (SCD)。 紅細胞的異常破壞導致貧血，從而阻塞血管並引起多器官缺血損傷和急性疼痛。 SCD 影響數百萬人，尤其是地中海血統的人，包括西半球（中美洲、加勒比海、南美洲）、撒哈拉以南非洲、印度、沙特阿拉伯、希臘、意大利和土耳其。

骨髓移植和血液幹細胞移植用於治療鐮狀細胞病。 SCD 的臨床嚴重程度各不相同，從輕微的、有時未被注意到的問題到需要立即住院治療的嚴重影響。 藥物治療可作為對症治療。 新生兒篩查 (NBS) 還有助於檢測 SCD 並減少其對兒童和新生兒的影響。

COVID-19 影響分析

COVID-19 大流行幾乎影響了每個行業。 血紅蛋白病市場和許多其他行業，尤其是健康和製藥行業的顯著下滑，迫使醫療機構將大部分資金和時間集中在 COVID-19 上。 血紅蛋白病的治療中斷主要是由於醫院感染的風險。 血紅蛋白病患者需要特殊的醫療保健。 在大流行期間，對某些藥物和治療的需求顯著增加。 儘管如此，由於工廠關閉等限制，生產仍無法滿足必要的需求。

市場增長因素

欠發達國家的血紅蛋白病病例增加

儘管有關遺傳性血紅蛋白疾病確切患病率的數據有限，但它們無疑給醫療保健資源帶來了沉重負擔。 欠發達國家的公共衛生保健系統也在改善，因此，患有這些疾病的兒童的存活率正在提高，這意味著更多的患者將可以接受後期治療。。 遺傳性血紅蛋白病是最常見的孤立性疾病。

高研發投入

組織導向、安全且高效的基因編輯技術的發展促進了針對血紅蛋白相關疾病的各種基因療法的發展。 基因療法有可能治愈患者。 隨著新的有前途的治療方法的出現，希望整體治療費用會變得更便宜。 目前正在進行越來越多的試驗，以確定這些基因編輯/添加技術在挽救 β-核纖層氨基病中血紅蛋白生成的效率和安全性。

市場製約因素

臨床試驗失敗與治療風險高

造血幹細胞移植是目前治療鐮狀細胞病的唯一方法。 這種做法已經發展到足以為其適應症和管理制定臨床實踐指南。 然而，儘管有大量的方案，但只有少數患者接受了它們的治療。 此外，鐮狀細胞移植患者實體瘤的長期副作用也是一個值得關注的領域。 儘管醫學領域取得了快速進展，但血紅蛋白病仍然沒有確定的永久性治療方法。

按類型劃分的前景

按類型，血紅蛋白病市場分為地中海貧血、鐮狀細胞病等。 2021 年，地中海貧血細分市場在血紅蛋白病市場的收入份額最高。 這是因為地中海貧血是一種由基因變化引起的血液疾病。 地中海貧血有兩種主要類型。 一種是 α 地中海貧血，當 α 珠蛋白基因缺失或發生突變時就會發生這種情況。 另一種是 β-地中海貧血，它是由於 β-珠蛋白的產生髮生變化而發展起來的。

銷售渠道

按銷售渠道劃分，它分為醫院藥房、在線供應商、藥店和零售藥店。 2021 年，醫院藥房部門在血紅蛋白疾病市場中佔據了重要的收入份額。 這是因為它包括醫療保健服務，例如診斷、配藥、配藥、儲存、藥品和醫療器械的配藥以及患者諮詢。 它還擁有醫生和護士等醫療保健專業人員，可以有效、安全和高效地使用它。 在醫療機構中，醫院藥劑師是藥學的專業領域，在患者健康管理中發揮作用。

治療觀點

血紅蛋白病市場按治療方法細分為單克隆抗體藥物、ACE 抑製劑、羥基尿等。 2021 年，單克隆抗體藥物細分市場在血紅蛋白病市場的收入份額最大。 這是因為有足夠的藥物可用於治療，而且地中海貧血患者在單克隆抗體藥物治療後表現出健康的康復。 單克隆抗體類似於人體產生的抗體，模仿免疫系統的活動。 它是通過從血液中提取和克隆特異性抗體製成的。

區域展望

按地區劃分，分析了北美、歐洲、亞太地區和 LAMEA 的血紅蛋白病市場。 到 2021 年，北美地區將在血紅蛋白病市場中佔據最大的收入份額。 各種組織發起的意識計劃旨在傳播與血紅蛋白病相關的疾病以及研究和發現治療這些疾病的新療法的必要性。 來自疾病廣泛發現地區的移民增加以及新的和增強的治療劑的可用性也有望推動市場增長。

內容

第一章市場範圍與研究方法

  • 市場定義
  • 目的
  • 市場規模
  • 細分
    • 全球血紅蛋白紊亂市場，按類型
    • 全球血紅蛋白紊亂市場：按分銷渠道分類
    • 全球血紅蛋白紊亂市場：按治療分類
    • 全球血紅蛋白紊亂市場：按地區
  • 調查方法

第 2 章市場概述

  • 簡介
    • 簡介
      • 市場構成和情景
  • 影響市場的主要因素
    • 市場驅動因素
    • 市場製約因素

第 3 章全球血紅蛋白病市場：按類型

  • 全球地中海貧血市場：按地區
  • 全球鐮狀細胞病市場：按地區
  • 世界其他地區市場：按地區

第 4 章全球血紅蛋白疾病市場（按分銷渠道）

  • 全球藥店和零售藥店市場，按地區
  • 全球住院藥房市場：按地區
  • 按地區劃分的全球在線提供商市場

第 5 章全球血紅蛋白疾病治療市場

  • 按地區劃分的單克隆抗體產品全球市場
  • 全球羥基尿市場：按地區
  • ACE 抑製劑的全球市場（按區域劃分）
  • 其他世界市場：按地區

第 6 章全球血紅蛋白病市場：按地區

  • 北美
    • 北美的血紅蛋白疾病市場（按國家/地區劃分）
      • 美國
      • 加拿大
      • 墨西哥
      • 其他北美地區
  • 歐洲
    • 按國家/地區劃分的歐洲血紅蛋白紊亂市場
      • 德國
      • 英國
      • 法國
      • 俄羅斯
      • 西班牙
      • 意大利
      • 其他歐洲
  • 亞太地區
    • 亞太地區按國家/地區劃分的血紅蛋白病市場
      • 中國
      • 日本
      • 印度
      • 韓國
      • 新加坡
      • 馬來西亞
      • 其他亞太地區
  • 拉美
    • LAMEA 血紅蛋白病市場：按國家/地區分類
      • 巴西
      • 阿根廷
      • 阿聯酋
      • 沙特阿拉伯
      • 南非
      • 尼日利亞
      • 其他拉美地區

第七章公司簡介

  • Abbott Laboratories
  • Sanofi S.A
  • Danaher Corporation
  • Pfizer, Inc.（Global Blood Therapeutics, Inc.）
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
  • Alnylam Pharmaceuticals, Inc.
  • Emmaus Life Sciences, Inc.
  • Biogen, Inc.
  • Canthera Discovery Ltd.

The Global Hemoglobinopathies Market size is expected to reach $6.0 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.

In its stable state, normal human hemoglobin's are tetrameric protein composed of two globin chains, each of which has an alpha (α-like) chain and a beta (B-like) chain. Every globin chain is attached to a heme moiety that contains iron. The synthesis of alpha-like and beta-like (also known as non-alpha-like) is maintained throughout the lifetime, so their ratio remains constant. In the human body, hemoglobin is used to transport oxygen from the lungs to tissues.

This happens as the globin chains enable the molecules to take up more oxygen in places with high oxygen concentrations and release oxygen in areas with low oxygen concentrations. Hemoglobin also transports carbon dioxide and nitric oxides. Hemoglobinopathies are a set of hereditary diseases. In these diseases, there is an abnormal synthesis or structure of the hemoglobin molecules.

For example, one such blood condition caused due to unstable hemoglobin that deforms or damages the red blood cells is called sickle cell disease (SCD). The unusual red blood cell breakdown causes anemia and clogs the blood vessels, leading to multi-organ ischemic damage and acute pain. Millions of individuals are affected by SCD, especially those whose ancestral origin is from Western Hemisphere (Central America, Caribbean, and South America), Sub-Saharan Africa, India, Saudi Arabia, and Mediterranean counties like Greece, Italy, and Turkey.

Bone marrow transplants and blood stem cells are used to treat Children with sickle cell disease. The clinical intensity of SCD varies, ranging from minor problems that sometimes go unnoticed to severe effects that need urgent hospitalization. There are medications for symptomatic effects. Also, newborn screening (NBS) can help discover SCD to lessen some of the disease's impact on children and newborns.

COVID - 19 Impact Analysis

The COVID-19 pandemic has affected nearly all industries; it has forced healthcare organizations to concentrate the majority of funds and time on fighting COVID-19, due to a significant drop in the hemoglobinopathies market and many other sectors, especially in health and pharmaceutical, was reported. The interruptions in treating hemoglobinopathy patients were primarily due to the risk of infection in the hospitals. Special health needs are required for patients with hemoglobinopathy. The demand for several drugs and treatments has significantly increased during the pandemic. Still, due to the shutdown of factories and other restrictions, production was unable to meet the required needs.

Market Growth Factors

The rising cases of hemoglobinopathy in under-developed countries

There is a limitation in data related to the exact number of inherited hemoglobin illnesses, but still, they are certainly going to be a major burden for healthcare resources. The public healthcare system in under-developed countries is also improving, and with that, the survival rate of children suffering from these diseases is also increasing, which means more patients will be available for later treatments. Inherited hemoglobin disorder is considered to be the most common monogenic illness.

High investments in research and development

The growth of tissue-oriented, safe, and efficient gene editing technology has contributed to the development of various gene therapy types for hemoglobin-related illnesses. Gene therapy has the potential to treat patients. As new and promising therapeutic options appear, the overall cost of treatment is expected to get more affordable. Presently, an increasing number of trials to find the efficiency and safety of these gene editing and addition technologies to rescue hemoglobin production in beta laminopathies are going on.

Market Restraining Factors

Failure of the clinical trials and high risk in treatment

A hematopoietic stem cell transplant is currently the only available treatment for Sickle Cell Disease. This approach has evolved enough to have resulted in practice guidelines for its indication and management. But despite the numerous protocols, the number of patients treated with them is only a few. Moreover, the long-term side effects of solid tumors in transplanted Sickle cell patients are also an area of concern. Although there is constant advancement in the medical sector, there is still a lack of permanent treatment for hemoglobinopathy illness.

Type Outlook

Based on the Type, the Hemoglobinopathy Market is segmented into Thalassemia, Sickle Cell Disease and Others. The thalassemia segment acquired the highest revenue share in the hemoglobinopathies market in 2021. It is because thalassemia is a type of blood disorder that is caused by the alteration in the gene. There are two primary types of thalassemia. One is alpha thalassemia which occurs when the alpha globin protein gene or genes are missing or mutated. And the other one is Beta thalassemia which is due to the change in the production of beta globin protein.

Distribution Channel Outlook

By Distribution channel, the is classified into Hospital Pharmacy, Online Providers and Drug Stores and Retail Pharmacy. The Hospital pharmacy segment recorded a significant revenue share in the hemoglobinopathies market in 2021. Due to the composition of the healthcare services, which includes the practice, preparing, compounding, storing, dispensing medicines and medical devices, and patient counseling. Also, they have healthcare professionals like doctors and nurses for effective, safe, and efficient use. In health facilities, a hospital pharmacy is a specialized field of pharmacy which is a part of the patient's health care.

Therapy Outlook

On the basis of Therapy, the hemoglobinopathy market is divided into Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea and Others. The Monoclonal Antibody Medication segment procured the largest revenue share in the hemoglobinopathy market in 2021. It is because of the sufficient medications available for the therapy and also because thalassemia patients show healthy recovery by monoclonal antibody medication. Monoclonal antibodies are similar to antibodies that a human body develops, which mimic the activity of the immune system. They are created through a process in which specific antibodies are drawn out of the blood and then cloned.

Regional Outlook

Region-wise, the hemoglobinopathies market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the largest revenue share in the hemoglobinopathies market in 2021. Due to the awareness programs initiated by the different organizations in which they spread awareness about the diseases related to hemoglobinopathy and the need to research and find new therapies for its treatment. Also, the rising immigration to the region from areas where this disease is widely found and the availability of new and enhanced medications are expected to fuel the market growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Thalassemia
  • Sickle Cell Disease
  • Others

By Distribution Channel

  • Drug Stores & Retail Pharmacy
  • Hospital Pharmacy
  • Online Providers

By Therapy

  • Monoclonal Antibody Medication
  • Hydroxyurea
  • ACE Inhibitors
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Abbott Laboratories
  • Sanofi S.A.
  • Danaher Corporation
  • Pfizer, Inc. (Global Blood Therapeutics, Inc.)
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
  • Alnylam Pharmaceuticals, Inc.
  • Emmaus Life Sciences, Inc.
  • Biogen, Inc.
  • Canthera Discovery Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Hemoglobinopathies Market, by Type
    • 1.4.2 Global Hemoglobinopathies Market, by Distribution Channel
    • 1.4.3 Global Hemoglobinopathies Market, by Therapy
    • 1.4.4 Global Hemoglobinopathies Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and Scenarios
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Hemoglobinopathies Market by Type

  • 3.1 Global Thalassemia Market by Region
  • 3.2 Global Sickle Cell Disease Market by Region
  • 3.3 Global Others Market by Region

Chapter 4. Global Hemoglobinopathies Market by Distribution Channel

  • 4.1 Global Drug Stores & Retail Pharmacy Market by Region
  • 4.2 Global Hospital Pharmacy Market by Region
  • 4.3 Global Online Providers Market by Region

Chapter 5. Global Hemoglobinopathies Market by Therapy

  • 5.1 Global Monoclonal Antibody Medication Market by Region
  • 5.2 Global Hydroxyurea Market by Region
  • 5.3 Global ACE Inhibitors Market by Region
  • 5.4 Global Others Market by Region

Chapter 6. Global Hemoglobinopathies Market by Region

  • 6.1 North America Hemoglobinopathies Market
    • 6.1.1 North America Hemoglobinopathies Market by Type
      • 6.1.1.1 North America Thalassemia Market by Country
      • 6.1.1.2 North America Sickle Cell Disease Market by Country
      • 6.1.1.3 North America Others Market by Country
    • 6.1.2 North America Hemoglobinopathies Market by Distribution Channel
      • 6.1.2.1 North America Drug Stores & Retail Pharmacy Market by Country
      • 6.1.2.2 North America Hospital Pharmacy Market by Country
      • 6.1.2.3 North America Online Providers Market by Country
    • 6.1.3 North America Hemoglobinopathies Market by Therapy
      • 6.1.3.1 North America Monoclonal Antibody Medication Market by Country
      • 6.1.3.2 North America Hydroxyurea Market by Country
      • 6.1.3.3 North America ACE Inhibitors Market by Country
      • 6.1.3.4 North America Others Market by Country
    • 6.1.4 North America Hemoglobinopathies Market by Country
      • 6.1.4.1 US Hemoglobinopathies Market
        • 6.1.4.1.1 US Hemoglobinopathies Market by Type
        • 6.1.4.1.2 US Hemoglobinopathies Market by Distribution Channel
        • 6.1.4.1.3 US Hemoglobinopathies Market by Therapy
      • 6.1.4.2 Canada Hemoglobinopathies Market
        • 6.1.4.2.1 Canada Hemoglobinopathies Market by Type
        • 6.1.4.2.2 Canada Hemoglobinopathies Market by Distribution Channel
        • 6.1.4.2.3 Canada Hemoglobinopathies Market by Therapy
      • 6.1.4.3 Mexico Hemoglobinopathies Market
        • 6.1.4.3.1 Mexico Hemoglobinopathies Market by Type
        • 6.1.4.3.2 Mexico Hemoglobinopathies Market by Distribution Channel
        • 6.1.4.3.3 Mexico Hemoglobinopathies Market by Therapy
      • 6.1.4.4 Rest of North America Hemoglobinopathies Market
        • 6.1.4.4.1 Rest of North America Hemoglobinopathies Market by Type
        • 6.1.4.4.2 Rest of North America Hemoglobinopathies Market by Distribution Channel
        • 6.1.4.4.3 Rest of North America Hemoglobinopathies Market by Therapy
  • 6.2 Europe Hemoglobinopathies Market
    • 6.2.1 Europe Hemoglobinopathies Market by Type
      • 6.2.1.1 Europe Thalassemia Market by Country
      • 6.2.1.2 Europe Sickle Cell Disease Market by Country
      • 6.2.1.3 Europe Others Market by Country
    • 6.2.2 Europe Hemoglobinopathies Market by Distribution Channel
      • 6.2.2.1 Europe Drug Stores & Retail Pharmacy Market by Country
      • 6.2.2.2 Europe Hospital Pharmacy Market by Country
      • 6.2.2.3 Europe Online Providers Market by Country
    • 6.2.3 Europe Hemoglobinopathies Market by Therapy
      • 6.2.3.1 Europe Monoclonal Antibody Medication Market by Country
      • 6.2.3.2 Europe Hydroxyurea Market by Country
      • 6.2.3.3 Europe ACE Inhibitors Market by Country
      • 6.2.3.4 Europe Others Market by Country
    • 6.2.4 Europe Hemoglobinopathies Market by Country
      • 6.2.4.1 Germany Hemoglobinopathies Market
        • 6.2.4.1.1 Germany Hemoglobinopathies Market by Type
        • 6.2.4.1.2 Germany Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.1.3 Germany Hemoglobinopathies Market by Therapy
      • 6.2.4.2 UK Hemoglobinopathies Market
        • 6.2.4.2.1 UK Hemoglobinopathies Market by Type
        • 6.2.4.2.2 UK Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.2.3 UK Hemoglobinopathies Market by Therapy
      • 6.2.4.3 France Hemoglobinopathies Market
        • 6.2.4.3.1 France Hemoglobinopathies Market by Type
        • 6.2.4.3.2 France Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.3.3 France Hemoglobinopathies Market by Therapy
      • 6.2.4.4 Russia Hemoglobinopathies Market
        • 6.2.4.4.1 Russia Hemoglobinopathies Market by Type
        • 6.2.4.4.2 Russia Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.4.3 Russia Hemoglobinopathies Market by Therapy
      • 6.2.4.5 Spain Hemoglobinopathies Market
        • 6.2.4.5.1 Spain Hemoglobinopathies Market by Type
        • 6.2.4.5.2 Spain Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.5.3 Spain Hemoglobinopathies Market by Therapy
      • 6.2.4.6 Italy Hemoglobinopathies Market
        • 6.2.4.6.1 Italy Hemoglobinopathies Market by Type
        • 6.2.4.6.2 Italy Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.6.3 Italy Hemoglobinopathies Market by Therapy
      • 6.2.4.7 Rest of Europe Hemoglobinopathies Market
        • 6.2.4.7.1 Rest of Europe Hemoglobinopathies Market by Type
        • 6.2.4.7.2 Rest of Europe Hemoglobinopathies Market by Distribution Channel
        • 6.2.4.7.3 Rest of Europe Hemoglobinopathies Market by Therapy
  • 6.3 Asia Pacific Hemoglobinopathies Market
    • 6.3.1 Asia Pacific Hemoglobinopathies Market by Type
      • 6.3.1.1 Asia Pacific Thalassemia Market by Country
      • 6.3.1.2 Asia Pacific Sickle Cell Disease Market by Country
      • 6.3.1.3 Asia Pacific Others Market by Country
    • 6.3.2 Asia Pacific Hemoglobinopathies Market by Distribution Channel
      • 6.3.2.1 Asia Pacific Drug Stores & Retail Pharmacy Market by Country
      • 6.3.2.2 Asia Pacific Hospital Pharmacy Market by Country
      • 6.3.2.3 Asia Pacific Online Providers Market by Country
    • 6.3.3 Asia Pacific Hemoglobinopathies Market by Therapy
      • 6.3.3.1 Asia Pacific Monoclonal Antibody Medication Market by Country
      • 6.3.3.2 Asia Pacific Hydroxyurea Market by Country
      • 6.3.3.3 Asia Pacific ACE Inhibitors Market by Country
      • 6.3.3.4 Asia Pacific Others Market by Country
    • 6.3.4 Asia Pacific Hemoglobinopathies Market by Country
      • 6.3.4.1 China Hemoglobinopathies Market
        • 6.3.4.1.1 China Hemoglobinopathies Market by Type
        • 6.3.4.1.2 China Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.1.3 China Hemoglobinopathies Market by Therapy
      • 6.3.4.2 Japan Hemoglobinopathies Market
        • 6.3.4.2.1 Japan Hemoglobinopathies Market by Type
        • 6.3.4.2.2 Japan Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.2.3 Japan Hemoglobinopathies Market by Therapy
      • 6.3.4.3 India Hemoglobinopathies Market
        • 6.3.4.3.1 India Hemoglobinopathies Market by Type
        • 6.3.4.3.2 India Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.3.3 India Hemoglobinopathies Market by Therapy
      • 6.3.4.4 South Korea Hemoglobinopathies Market
        • 6.3.4.4.1 South Korea Hemoglobinopathies Market by Type
        • 6.3.4.4.2 South Korea Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.4.3 South Korea Hemoglobinopathies Market by Therapy
      • 6.3.4.5 Singapore Hemoglobinopathies Market
        • 6.3.4.5.1 Singapore Hemoglobinopathies Market by Type
        • 6.3.4.5.2 Singapore Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.5.3 Singapore Hemoglobinopathies Market by Therapy
      • 6.3.4.6 Malaysia Hemoglobinopathies Market
        • 6.3.4.6.1 Malaysia Hemoglobinopathies Market by Type
        • 6.3.4.6.2 Malaysia Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.6.3 Malaysia Hemoglobinopathies Market by Therapy
      • 6.3.4.7 Rest of Asia Pacific Hemoglobinopathies Market
        • 6.3.4.7.1 Rest of Asia Pacific Hemoglobinopathies Market by Type
        • 6.3.4.7.2 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel
        • 6.3.4.7.3 Rest of Asia Pacific Hemoglobinopathies Market by Therapy
  • 6.4 LAMEA Hemoglobinopathies Market
    • 6.4.1 LAMEA Hemoglobinopathies Market by Type
      • 6.4.1.1 LAMEA Thalassemia Market by Country
      • 6.4.1.2 LAMEA Sickle Cell Disease Market by Country
      • 6.4.1.3 LAMEA Others Market by Country
    • 6.4.2 LAMEA Hemoglobinopathies Market by Distribution Channel
      • 6.4.2.1 LAMEA Drug Stores & Retail Pharmacy Market by Country
      • 6.4.2.2 LAMEA Hospital Pharmacy Market by Country
      • 6.4.2.3 LAMEA Online Providers Market by Country
    • 6.4.3 LAMEA Hemoglobinopathies Market by Therapy
      • 6.4.3.1 LAMEA Monoclonal Antibody Medication Market by Country
      • 6.4.3.2 LAMEA Hydroxyurea Market by Country
      • 6.4.3.3 LAMEA ACE Inhibitors Market by Country
      • 6.4.3.4 LAMEA Others Market by Country
    • 6.4.4 LAMEA Hemoglobinopathies Market by Country
      • 6.4.4.1 Brazil Hemoglobinopathies Market
        • 6.4.4.1.1 Brazil Hemoglobinopathies Market by Type
        • 6.4.4.1.2 Brazil Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.1.3 Brazil Hemoglobinopathies Market by Therapy
      • 6.4.4.2 Argentina Hemoglobinopathies Market
        • 6.4.4.2.1 Argentina Hemoglobinopathies Market by Type
        • 6.4.4.2.2 Argentina Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.2.3 Argentina Hemoglobinopathies Market by Therapy
      • 6.4.4.3 UAE Hemoglobinopathies Market
        • 6.4.4.3.1 UAE Hemoglobinopathies Market by Type
        • 6.4.4.3.2 UAE Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.3.3 UAE Hemoglobinopathies Market by Therapy
      • 6.4.4.4 Saudi Arabia Hemoglobinopathies Market
        • 6.4.4.4.1 Saudi Arabia Hemoglobinopathies Market by Type
        • 6.4.4.4.2 Saudi Arabia Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.4.3 Saudi Arabia Hemoglobinopathies Market by Therapy
      • 6.4.4.5 South Africa Hemoglobinopathies Market
        • 6.4.4.5.1 South Africa Hemoglobinopathies Market by Type
        • 6.4.4.5.2 South Africa Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.5.3 South Africa Hemoglobinopathies Market by Therapy
      • 6.4.4.6 Nigeria Hemoglobinopathies Market
        • 6.4.4.6.1 Nigeria Hemoglobinopathies Market by Type
        • 6.4.4.6.2 Nigeria Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.6.3 Nigeria Hemoglobinopathies Market by Therapy
      • 6.4.4.7 Rest of LAMEA Hemoglobinopathies Market
        • 6.4.4.7.1 Rest of LAMEA Hemoglobinopathies Market by Type
        • 6.4.4.7.2 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel
        • 6.4.4.7.3 Rest of LAMEA Hemoglobinopathies Market by Therapy

Chapter 7. Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
    • 7.1.5 SWOT Analysis
  • 7.2 Sanofi S.A.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expense
    • 7.2.5 Recent strategies and developments:
      • 7.2.5.1 Trials and Approvals:
  • 7.3 Danaher Corporation
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expense
  • 7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional & Segmental Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Partnerships, Collaborations, and Agreements:
      • 7.4.5.2 Approvals and Trials:
  • 7.5 Merck & Co., Inc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expenses
  • 7.6 Bristol Myers Squibb Company
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expenses
  • 7.7 Alnylam Pharmaceuticals, Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Research & Development Expense
  • 7.8 Emmaus Life Sciences, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Research & Development Expenses
  • 7.9 Biogen, Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Regional Analysis
    • 7.9.4 Research & Development Expense
  • 7.10. Canthera Discovery Ltd.
    • 7.10.1 Company Overview

LIST OF TABLES

  • TABLE 1 Global Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 2 Global Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 3 Global Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Global Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Global Thalassemia Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Thalassemia Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Sickle Cell Disease Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Sickle Cell Disease Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 12 Global Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 13 Global Drug Stores & Retail Pharmacy Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Drug Stores & Retail Pharmacy Market by Region, 2022 - 2028, USD Million
  • TABLE 15 Global Hospital Pharmacy Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Hospital Pharmacy Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Online Providers Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Online Providers Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 20 Global Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 21 Global Monoclonal Antibody Medication Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global Monoclonal Antibody Medication Market by Region, 2022 - 2028, USD Million
  • TABLE 23 Global Hydroxyurea Market by Region, 2018 - 2021, USD Million
  • TABLE 24 Global Hydroxyurea Market by Region, 2022 - 2028, USD Million
  • TABLE 25 Global ACE Inhibitors Market by Region, 2018 - 2021, USD Million
  • TABLE 26 Global ACE Inhibitors Market by Region, 2022 - 2028, USD Million
  • TABLE 27 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 28 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 29 Global Hemoglobinopathies Market by Region, 2018 - 2021, USD Million
  • TABLE 30 Global Hemoglobinopathies Market by Region, 2022 - 2028, USD Million
  • TABLE 31 North America Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 32 North America Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 33 North America Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 34 North America Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 35 North America Thalassemia Market by Country, 2018 - 2021, USD Million
  • TABLE 36 North America Thalassemia Market by Country, 2022 - 2028, USD Million
  • TABLE 37 North America Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 38 North America Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 39 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 40 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 41 North America Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 42 North America Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 43 North America Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 45 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 46 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 47 North America Online Providers Market by Country, 2018 - 2021, USD Million
  • TABLE 48 North America Online Providers Market by Country, 2022 - 2028, USD Million
  • TABLE 49 North America Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 50 North America Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 51 North America Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
  • TABLE 52 North America Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
  • TABLE 53 North America Hydroxyurea Market by Country, 2018 - 2021, USD Million
  • TABLE 54 North America Hydroxyurea Market by Country, 2022 - 2028, USD Million
  • TABLE 55 North America ACE Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 56 North America ACE Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 57 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 58 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 59 North America Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
  • TABLE 60 North America Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
  • TABLE 61 US Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 62 US Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 63 US Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 64 US Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 65 US Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 66 US Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 67 US Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 68 US Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 69 Canada Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 70 Canada Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 71 Canada Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 72 Canada Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 73 Canada Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 74 Canada Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 75 Canada Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 76 Canada Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 77 Mexico Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 78 Mexico Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 79 Mexico Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 80 Mexico Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 81 Mexico Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 82 Mexico Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 83 Mexico Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 84 Mexico Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 85 Rest of North America Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 86 Rest of North America Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 87 Rest of North America Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 88 Rest of North America Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 89 Rest of North America Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 90 Rest of North America Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 91 Rest of North America Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 92 Rest of North America Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 93 Europe Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 94 Europe Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 95 Europe Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 96 Europe Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 97 Europe Thalassemia Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Europe Thalassemia Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Europe Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 100 Europe Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 101 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 102 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 103 Europe Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 104 Europe Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 105 Europe Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 106 Europe Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 107 Europe Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 108 Europe Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 109 Europe Online Providers Market by Country, 2018 - 2021, USD Million
  • TABLE 110 Europe Online Providers Market by Country, 2022 - 2028, USD Million
  • TABLE 111 Europe Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 112 Europe Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 113 Europe Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
  • TABLE 114 Europe Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
  • TABLE 115 Europe Hydroxyurea Market by Country, 2018 - 2021, USD Million
  • TABLE 116 Europe Hydroxyurea Market by Country, 2022 - 2028, USD Million
  • TABLE 117 Europe ACE Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 118 Europe ACE Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 119 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 120 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 121 Europe Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
  • TABLE 122 Europe Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
  • TABLE 123 Germany Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 124 Germany Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 125 Germany Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 126 Germany Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 127 Germany Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 128 Germany Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 129 Germany Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 130 Germany Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 131 UK Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 132 UK Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 133 UK Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 134 UK Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 135 UK Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 136 UK Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 137 UK Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 138 UK Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 139 France Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 140 France Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 141 France Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 142 France Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 143 France Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 144 France Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 145 France Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 146 France Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 147 Russia Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 148 Russia Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 149 Russia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 150 Russia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 151 Russia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 152 Russia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 153 Russia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 154 Russia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 155 Spain Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 156 Spain Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 157 Spain Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 158 Spain Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 159 Spain Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 160 Spain Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 161 Spain Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 162 Spain Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 163 Italy Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 164 Italy Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 165 Italy Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 166 Italy Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 167 Italy Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 168 Italy Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 169 Italy Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 170 Italy Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 171 Rest of Europe Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 172 Rest of Europe Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 173 Rest of Europe Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 174 Rest of Europe Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 175 Rest of Europe Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 176 Rest of Europe Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 177 Rest of Europe Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 178 Rest of Europe Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 179 Asia Pacific Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 180 Asia Pacific Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 181 Asia Pacific Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 182 Asia Pacific Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 183 Asia Pacific Thalassemia Market by Country, 2018 - 2021, USD Million
  • TABLE 184 Asia Pacific Thalassemia Market by Country, 2022 - 2028, USD Million
  • TABLE 185 Asia Pacific Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 186 Asia Pacific Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 187 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 188 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 189 Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 190 Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 191 Asia Pacific Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 192 Asia Pacific Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 193 Asia Pacific Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 194 Asia Pacific Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 195 Asia Pacific Online Providers Market by Country, 2018 - 2021, USD Million
  • TABLE 196 Asia Pacific Online Providers Market by Country, 2022 - 2028, USD Million
  • TABLE 197 Asia Pacific Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 198 Asia Pacific Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 199 Asia Pacific Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
  • TABLE 200 Asia Pacific Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
  • TABLE 201 Asia Pacific Hydroxyurea Market by Country, 2018 - 2021, USD Million
  • TABLE 202 Asia Pacific Hydroxyurea Market by Country, 2022 - 2028, USD Million
  • TABLE 203 Asia Pacific ACE Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 204 Asia Pacific ACE Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 205 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 206 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 207 Asia Pacific Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
  • TABLE 208 Asia Pacific Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
  • TABLE 209 China Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 210 China Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 211 China Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 212 China Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 213 China Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 214 China Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 215 China Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 216 China Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 217 Japan Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 218 Japan Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 219 Japan Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 220 Japan Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 221 Japan Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 222 Japan Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 223 Japan Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 224 Japan Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 225 India Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 226 India Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 227 India Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 228 India Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 229 India Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 230 India Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 231 India Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 232 India Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 233 South Korea Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 234 South Korea Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 235 South Korea Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 236 South Korea Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 237 South Korea Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 238 South Korea Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 239 South Korea Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 240 South Korea Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 241 Singapore Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 242 Singapore Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 243 Singapore Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 244 Singapore Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 245 Singapore Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 246 Singapore Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 247 Singapore Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 248 Singapore Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 249 Malaysia Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 250 Malaysia Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 251 Malaysia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 252 Malaysia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 253 Malaysia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 254 Malaysia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 255 Malaysia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 256 Malaysia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 257 Rest of Asia Pacific Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 258 Rest of Asia Pacific Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 259 Rest of Asia Pacific Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 260 Rest of Asia Pacific Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 261 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 262 Rest of Asia Pacific Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 263 Rest of Asia Pacific Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 264 Rest of Asia Pacific Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 265 LAMEA Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 266 LAMEA Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 267 LAMEA Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 268 LAMEA Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 269 LAMEA Thalassemia Market by Country, 2018 - 2021, USD Million
  • TABLE 270 LAMEA Thalassemia Market by Country, 2022 - 2028, USD Million
  • TABLE 271 LAMEA Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
  • TABLE 272 LAMEA Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
  • TABLE 273 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 274 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 275 LAMEA Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 276 LAMEA Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 277 LAMEA Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 278 LAMEA Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 279 LAMEA Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
  • TABLE 280 LAMEA Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
  • TABLE 281 LAMEA Online Providers Market by Country, 2018 - 2021, USD Million
  • TABLE 282 LAMEA Online Providers Market by Country, 2022 - 2028, USD Million
  • TABLE 283 LAMEA Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 284 LAMEA Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 285 LAMEA Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
  • TABLE 286 LAMEA Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
  • TABLE 287 LAMEA Hydroxyurea Market by Country, 2018 - 2021, USD Million
  • TABLE 288 LAMEA Hydroxyurea Market by Country, 2022 - 2028, USD Million
  • TABLE 289 LAMEA ACE Inhibitors Market by Country, 2018 - 2021, USD Million
  • TABLE 290 LAMEA ACE Inhibitors Market by Country, 2022 - 2028, USD Million
  • TABLE 291 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 292 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 293 LAMEA Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
  • TABLE 294 LAMEA Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
  • TABLE 295 Brazil Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 296 Brazil Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 297 Brazil Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 298 Brazil Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 299 Brazil Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 300 Brazil Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 301 Brazil Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 302 Brazil Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 303 Argentina Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 304 Argentina Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 305 Argentina Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 306 Argentina Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 307 Argentina Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 308 Argentina Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 309 Argentina Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 310 Argentina Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 311 UAE Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 312 UAE Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 313 UAE Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 314 UAE Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 315 UAE Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 316 UAE Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 317 UAE Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 318 UAE Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 319 Saudi Arabia Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 320 Saudi Arabia Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 321 Saudi Arabia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 322 Saudi Arabia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 323 Saudi Arabia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 324 Saudi Arabia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 325 Saudi Arabia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 326 Saudi Arabia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 327 South Africa Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 328 South Africa Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 329 South Africa Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 330 South Africa Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 331 South Africa Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 332 South Africa Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 333 South Africa Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 334 South Africa Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 335 Nigeria Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 336 Nigeria Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 337 Nigeria Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 338 Nigeria Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 339 Nigeria Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 340 Nigeria Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 341 Nigeria Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 342 Nigeria Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 343 Rest of LAMEA Hemoglobinopathies Market, 2018 - 2021, USD Million
  • TABLE 344 Rest of LAMEA Hemoglobinopathies Market, 2022 - 2028, USD Million
  • TABLE 345 Rest of LAMEA Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
  • TABLE 346 Rest of LAMEA Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
  • TABLE 347 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
  • TABLE 348 Rest of LAMEA Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
  • TABLE 349 Rest of LAMEA Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
  • TABLE 350 Rest of LAMEA Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
  • TABLE 351 Key Information - Abbott Laboratories
  • TABLE 352 Key Information - Sanofi S.A.
  • TABLE 353 Key Information - Danaher Corporation
  • TABLE 354 Key Information - Pfizer, Inc.
  • TABLE 355 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 356 Key Information - Bristol Myers Squibb Company
  • TABLE 357 Key Information - Alnylam Pharmaceuticals, Inc.
  • TABLE 358 Key Information - Emmaus Life Sciences, INC.
  • TABLE 359 Key Information - Biogen, Inc.
  • TABLE 360 Key Information - Canthera Discovery Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Hemoglobinopathies Market Share by Type, 2021
  • FIG 3 Global Hemoglobinopathies Market Share by Type, 2028
  • FIG 4 Global Hemoglobinopathies Market by Type, 2018 - 2028, USD Million
  • FIG 5 Global Hemoglobinopathies Market Share by Distribution Channel, 2021
  • FIG 6 Global Hemoglobinopathies Market Share by Distribution Channel, 2028
  • FIG 7 Global Hemoglobinopathies Market by Distribution Channel, 2018 - 2028, USD Million
  • FIG 8 Global Hemoglobinopathies Market Share by Therapy, 2021
  • FIG 9 Global Hemoglobinopathies Market Share by Therapy, 2028
  • FIG 10 Global Hemoglobinopathies Market by Therapy, 2018 - 2028, USD Million
  • FIG 11 Global Hemoglobinopathies Market Share by Region, 2021
  • FIG 12 Global Hemoglobinopathies Market Share by Region, 2028
  • FIG 13 Global Hemoglobinopathies Market by Region, 2018 - 2028, USD Million
  • FIG 14 Swot analysis: Abbott laboratories